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Osteoporosis (OP) is a complex bone metabolic disease indicated by excess bone 
resorption over bone formation. Some cannabinoid receptor 2 (CB2) inverse agonists have 
shown dual antiresoptive and anabolic effects, and thus are potential anti-OP agents. However, 
the underlying mechanism, especially for their anabolic effects, is not very clear. To fully 
understand the pharmaceutical roles of CB2 inverse agonists, we implement polypharmacology 
analysis by using two off-target prediction tools (HTDocking and TargetHunter). First, we 
construct osteoporosis domain specific knowledgebase (OP-KB) that contains the data of anti-
OP targets, related proteins, drugs, and chemicals collected from a variety of available databases. 
Five approved anti-OP drugs undergo HTDocking to screen all OP-related proteins in OP-KB for 
the detection of potential off-targets. This prediction validates the reliability of HTDocking 
method in OP-KB based on the concordance of actual and predicted targets. Similarly, we 
analyze polypharmacological effects of six CB2 inverse agonists including two in-house 
compounds (Xie95-1042, Xie95-1171). Potential targets are predicted and ranked based on the 
degree of connectivity to drugs. To validate our prediction and reveal possible interaction modes, 
we perform molecular docking between two in-house compounds and AM630 with six top 
predicted targets that are all responsible for bone formation. We observe similar binding 
interactions between these three compounds with similar nearby residues in comparison to initial 
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crystal structures. Hence, we hypothesize that CB2 inverse agonists may act on other anti-
osteoporosis targets such as NOS3, DHI1, VDR, ALDH2, TRFL and ESR1 to achieve their 
anabolic effect for bone formation. In addition, TargetHunter is used to predict off-targets 
beyond OP-related protein list. Based on the prediction of two in-house compounds, aldehyde 
dehydrogenase 1A1 (ALDH1A1), a key protein involved in cancer development discovered 
recently, is probably another target for those two CB2 inverse agonists. This finding may imply 
new mechanism of the anti-cancer effect of CB2 inverse agonists, and also facilitate relevant 
drug repurposing. In summary, our approach provide a paradigm for polypharmacology study on 
a specific disease domain, which we believe can be widely applied to other complex diseases 
study to accelerate drug discovery. 
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1.0  INTRODUCTION 
1.1 OSTEOPOROSIS 
Osteoporosis has been a global public health problem that affects over 200 million people 
worldwide.[1] The high risk population includes men aged over 50 and menopausal women. 
Recent reports show in the United States alone, 52 million people are suffering from 
osteoporosis or are at risk of developing this disease.[2] Fracture is the most common 
complication of osteoporosis that brings costly consequences in both household and 
socioeconomic terms[3]—it is estimated that 40% of women and 15-30% of men with 
osteoporosis have a fracture during their lifetime with a related cost of 19 billion dollars each 
year in US.[4, 5] In addition, osteoporosis is responsible for more hospital days than diabetes, 
breast cancer or myocardial infarction.[6] 
 
Osteoporosis is associated with abnormal bone remodeling with increased ratio of bone 
resorption over bone formation. Bone remodeling is a continuous lifetime process where old 
bone cells are removed by the osteoclasts and new bone cells are deposited by the osteoblasts.[7] 
In the healthy human body, the balanced bone remodeling cycle facilitates repair of 
microdamage and provides calcium from bone tissue for cellular functions.[8] However, bone 
remodeling is accelerated in postmenopausal women and the aging population, leading to excess 
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bone resorption over bone formation, acute or sustained loss of bone mass, disrupted bone 
architecture, and finally the occurrence of osteoporosis.[9] The detailed mechanism of bone 
remodeling in osteoporosis is shown in Figure 1.  
 
Figure 1. Regulation of bone remodeling in osteoporosis by the endocannabinoid system. 
1)Remodeling starts when osteoclasts are activated, resorb bone, and create bone cavities. 
Osteoblast activation follows, as well as formation of osteoid, which fills in the bone cavities. 
Once the bone martix synthesis is done, osteoblasts become embedded in the matrix and function 
as osteocytes. However, in osteoporosis, bone remodeling occurs with excess bone resorption, 
resulting in unreversable bone loss. 2) The endocannabinoid system is mainly composed of 
cannabinoid receptors (CB) and cannabinoid receptor ligands (CBL). They are widely found in 
skeleton, including osteoclasts, osteoblasts, their precursors, and bone marrow stromal cells. 
They work together to control bone cell proliferation, differentiation and function. 
 
 3 
Currently, there are two therapeutic strategies for osteoporosis: one is antiresorptive 
therapy, which inhibits bone resorption; the other is anabolic therapy that is perceived to 
augment bone formation. However, all current marketed anti-OP drugs have shortcomings 
because of limited potency and potential for toxicities.[10] For instance, bisphosphonates, the 
first-line antiresorptive agents, eventually cause a decrease of osteoblast function in long-term 
use that is attributed to atypical bone fractures.[11] Another antiresorptive agent, Calcitonin, is 
recently withdrawn from the market in Europe due to its increased risk of cancer with long-term 
use.[12] On the other hand, the use of the anabolic agent, Teriaratide, is restricted in two years’ 
use due to increasing risk of osteosarcoma.[13] Taking the increasing health concern of 
osteoporosis and safety issue of currently available drugs together, there is great interest and 
demand in exploring new-generation drugs with novel mechanisms for the treatment of 
osteoporosis. The focus of current and future perspective would be better understanding of the 
biology of osteoclasts and osteoblasts and development of new drugs that can hold synergistic 
effect for both osteoclast and osteoblast regulation. 
1.2 CANNABINOID RECEPTOR 2 AND ITS ROLE IN OSTEOPOROSIS 
1.2.1 The skeletal endocannabinoid system 
The endocannabinoid system is composed of two cannabinoid receptors (cannabinoid 
receptor 1 (CB1) and cannabinoid receptor 2 (CB2)), their endogenous ligands (Anandamide and 
2-Arachidonylglycerol (2-AG)), and ligand metabolizing enzymes.[14] The endocannabinoid 
system has been recognized to play an important role in regulating a variety of physiological 
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processes and are involved in pharmacological effects against several diseases and disorders, 
such as pain,[15] immune and neurodegenerative disorders,[16, 17] cancer,[18] drug abuse,[19] 
cardiovascular and gastrointestinal disorders,[20] stroke and inflammation,[21, 22] etc.(Figure 
2). Hence, developing synthetic cannabinoids targeting the endocannabinoid system shows 
promise in therapies for these diseases.  
 
Figure 2. The endocannabinoid system and its role in diseases. Abbreviations are listed in 
Appendix A.    
 
In recent years, the skeletal endocannabinoid system and its therapeutic potential in 
osteoporosis have drawn extensive attention.[23-26] Several studies demonstrate its key role in 
adjusting the bone remodeling process by claiming that cannabinoid receptors, endocannabinoids 
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and their metabolizing enzymes are expressed in the skeleton (Figure 1), where they collaborate 
with each other to control bone cell proliferation, differentiation and function.[27] Moreover, the 
endocannabinoids are produced by osteoclasts and osteoblasts with similar level to those found 
in other organs.[27, 28] Also, the treatment with endocannabinoids is effective for ovariectomy-
induced bone loss in preclinical studies.[29, 30] 
 
Together with endocannabinoids, a growing number of synthetic cannabinoid receptor 
binding ligands are reported to influence bone cell proliferation and activity both in vivo and in 
vitro (Table 1.).[29-35] They includes agonists such as CP55490, WIN55212, HU308, etc., and 
inverse agonists such as AM630, SR144528, and Rimonabant, which upon binding to CB 
receptor can not only block agonist-induced receptor activation, but also reverse subsequent 
activity thereby modulating downstream signaling pathways in the opposite direction to those of 
classical agonists.[24] From Table 1, we can see that overall, the CB agonists can increase the 
number and activity of both osteoclasts and osteoblasts, which may be served as anabolic agents 
in osteoporosis therapy. On the other hand, CB inverse agonists, which behave as antiresorptive 
agents, can reduce the number and activity of both osteoblasts and osteoclasts. However, some 
inconsistent data arise between different groups. For example, HU308, a selective CB2 agonist, 
shows a stimulatory effect on osteoclast formation in the study of Dr. Idris’ group.[31] But in 
complete contrast, Orr Ofek and colleagues claim that HU308 can inhibit osteoclast 
formation.[30] For another case, AM630, a CB2-selective inverse agonist, inhibits osteoclast 
differentiation (IC50 = 0.33 μM) and suppressed osteoclast activity (IC50 = 7.2 μM) in vitro.[36] 
But at high concentration, AM630 can stimulate human osteoclast formation instead.[34] These 
conflicting data may result from complex pharmacological and off-target effects of certain CB 
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ligands, as well as unclear mechanisms of the influence that the CB receptor has on bone cell 
activity.  
Table 1. The role of cannabinoid receptor ligands in the regulation of osteoclast and 
osteoblast proliferation and activity in vitro and in vivo. 
  
Ligands Receptor 
Osteoclast 
number 
Osteoclast 
activity 
Osteoblast 
number 
Reference 
CB 
Agonists 
Anadamide CB1/CB2       [29] 
2-AG CB1/CB2       [29] 
CP55490 CB1/CB2       [30, 31] 
WIN55212 CB1 NT* NT   [30, 31] 
JWH133 CB2   NT   [31, 32] 
JWH015 CB2 NT     [31, 32] 
HU308 CB2   NT   [30, 31] 
CB Inverse 
agonists 
AM630 CB2       [34, 35] 
SR144528 CB2       [34, 35] 
AM251 CB1       [33] 
Rimonabant CB1       [33] 
 * Not tested. This table is modified based on the reference [23] 
1.2.2 Cannabinoid receptor 2 inverse agonist as treatment of osteoporosis 
Although both CB1 and CB2 ligands exhibit therapeutic potential in osteoporosis, CB2 
ligands have one inherent advantage. Unlike CB1 that is expressed predominantly in brain,[37] 
CB2 is primarily expressed in peripheral cells and tissues,[38] which provides an approach to 
avoiding psychotropic side effects caused by targeting CB1.[39] In particular for osteoporosis 
therapy, CB2 ligands hold more potential over CB1 ligands according to human genetic studies 
that indicated polymorphisms in CNR2 (the gene encoding CB2) were associated with 
postmenopausal osteoporosis.[40, 41] Moreover, osteoblasts, osteoclasts and osteocytes express 
CB2 receptors at a significantly higher level than that reported for CB1.[31, 34, 42] Taken 
together, selective targeting of CB2 over CB1 might shed light on the treatment of osteoporosis. 
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Our lab is focusing on the design and discovery of CB2 inverse agonists in the treatment 
of osteoporosis. A series of promising compounds has been discovered to show potent and 
selective CB2 binding and good osteoclast inhibition.[43, 44] Importantly, one of our 
compounds, Xie95-1042, shows anabolic effects by enhancing osteoblast activity at the 
concentration of 10-12 M[45] (Some data is not published). In agreement with this observation, 
the phytocannabinoid Tetrahydrocannabivarin, known as a CB2/CB1 inverse agonist with 
assumed inhibitory effect on bone formation, is reported to promote bone module formation.[33, 
46] Another reason for focusing on CB2 inverse agonist study is attributable to the 
aforementioned genetic study.32,33 The CB2 gene is validated to be associated with 
postmenopausal osteoporosis, and CB2 deficient mice are protected from ovariectomy-induced 
bone loss, which can be reproduced using CB2 inverse agonists.[24] 
 
In this thesis, we are exploring the mechanism of dual anti-OP functions of CB2 inverse 
agonists. One explanation could be the pharmacologic complexity of CB2 inverse agonists. They 
may act on diverse osteoporosis therapeutic targets or signaling pathways to accomplish a 
synergetic effect on both osteoclasts and osteoblasts.  
1.3 POLYPHARMACOLOGY AND DRUG DISCOVERY 
Polypharmacology describes the interaction of multiple drugs with multiple targets, 
which may be involved in a single or multiple disease pathways.[47] In recent years, 
conventional “one drug — one target” paradigm in drug discovery has been challenged by 
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“multiple drugs — multiple targets” mode advocated by the polypharmacology concept.[48, 49] 
Polypharmacology has gained prominent success in drug discovery for some complex diseases 
such as cancer[50] and psychiatric disorders,[51] in which most marketed drugs can interact with 
multiple disease-relevant targets to maximum therapeutic efficacy. On the other hand, 
polypharmacology is believed to prevent drug resistance due to mutations or expression 
changes.[52] Furthermore, polypharmacological drugs could be safer because of reduced on-
target adverse effects.[53] However, polypharmacology also brings about unintended antitarget-
caused adverse effects that must be avoided in drug development.[54] 
 
Given the complex nature of osteoporosis, polypharmacology study is designed to 
understand the cross-talk between therapeutic targets, signaling pathways-related proteins, and 
their binding drugs. This can not only help completely unravel the mechanism of action for 
existing drugs, but also predict possible off-target therapeutic/adverse effects and guide multiple 
drug combination therapy. A polypharmacology study for CB2 inverse agonists, in particular, 
may elucidate the conflicted outcomes of some compounds in modulating bone cell activity. 
Moreover, new therapeutic targets of osteoporosis may be predicted for CB2 inverse agonists for 
the use of drug repurposing. On the basis of other potential targets that CB2 inverse agonists may 
act on, multiple-target CB2 inverse agonists can be designed with anticipated greater efficacy 
and lower toxicity for the treatment of osteoporosis.  
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2.0  MATERIAL AND METHOD 
2.1 OSTEOPOROSIS  DOMAIN SPECIFIC KNOWLEDGEBASE (OP-KB) 
To provide a comprehensive platform for anti-OP drug discovery and particularly for a 
polypharmacological study, we data-mine the information of osteoporosis-related proteins, 
signaling pathways, therapeutic targets and their associated drugs from various public databases, 
and compiled them into our in-house osteoporosis domain specific knowledgebase (OP-KB) 
together with a cloud computing server: http://cbligand.org/OP. In fact, the disease domain 
specific knowledgebase was not a newborn concept in our group, which has gain success in 
building a drug abuse knowledgebase (DA-KB)[55] and an Alzheimer’s disease knowledgebase 
(ALzPlatform: http://www.cbligand.org/AD).[56] The current version of OP-KB contains the 
following features: 
 
1) Database infrastructure and web interface 
OP-KB is designed with a MySQL database (http://www.mysql.com) and an apache web 
server (http://www.apache.org) with OpenBabel[57] at the backend as the search engine for 
chemical structures. The web interface is written in PHP language (http://www.php.net).  
 
2) Data collection and content 
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The validated target data for osteoporosis therapy is collected according to approved 
drugs, clinical trials drugs, and discontinued drugs from a variety of public databases including 
Metacore,[58] DrugBank,[59] ClinicalTrials.gov,[60] BindingDB,[61] SuperTarget,[62] and 
ChEMBL database.[63] The information for drugs with unknown targets is also included. We 
further gather OP-related proteins information and corresponding signaling pathways from the 
KEGG pathway database.[64] Finally, all the chemical structures, bioactivity values, together 
with data for pathways, bioassays, and references are imported into OP-KB.  
 
3) Chemoinformatics Tools 
For facilitating in silico drug design for osteoporosis treatment, the OP-KB cloud 
computing server also integrate diverse chemoinformatics tools based on state-of-the-art machine 
learning algorithms developed by our group or from public resources. For example, this server 
employ the properties explorer (http://www.cbligand.org/OP/Property_Explorer.php) and the 
blood-brain barrier (BBB) predictor (http://www.cbligand.org/BBB) to analyze the drug-likeness 
of small molecules. It also applies the PAINS predictor (http://www.cbligand.org/PAINS) and 
the toxicity predictor (http://www.cbligand.org/Tox) which allow exclusion of molecules with 
potential safety issue in the early phase of drug discovery. To our interest of study, two of our 
developed polypharmacology analysis tools, HTDocking and TargetHunter, are imbedded as 
core functions in OP-KB. Detailed description can be found in section 2.2. 
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2.2 POLYPHARMACOLOGY ANALYSIS TOOLS 
2.2.1 HTDocking 
We have established a high-throughput docking program (HTDocking, 
http://cbligand.org/OP/docking_search.php), which is a web-interface computing tool that 
automates docking procedures to search for protein targets and explore ligand-protein 
interactions. In the current version of OP-KB, crystal structures of osteoporosis-related proteins 
have been collected from Protein Data Bank (http://www.rcsb.org/pdb)[65] to build an OP 
domain-specific subset by searching with a sequence from our database. Water molecules and 
ligands are removed if needed, hydrogen atoms are added, and the active site(s) of each protein 
are defined by the residues around the co-crystalized ligands or predicted using our published 
method.[66] Docking scores are used to assess and rank potential target proteins for a queried 
compound.  
2.2.2 TargetHunter 
Complementary to structure-based HTDocking tool, TargetHunter, a ligand-basedtool 
(http://www.cbligand.org/TargetHunter), has also been employed to predict potential off-targets 
of compounds. The detailed description of TargetHunter algorithm is elaborated in our recently 
published paper[67] based on a well-known medicinal chemistry principle: structurally similar 
compounds have similar physiochemical properties that may result in similar pharmaceutical 
profiles. TargetHunter is a powerful cloud computing tool with attractive features: (i) ease of 
use; (ii) query data retrieval function; (iii) user choices of desired fingerprints and databases; (iv) 
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high accuracy; and (v) Bioassay Finder function implemented in BioassayGeoMap program to 
facilitate users to find the laboratories who have published bioassay(s) for experimental 
validation. The combination of HTDocking and TargetHunter will assist researchers in 
conducting polypharmacology studies for off-target prediction and thereby develop bioactive 
compounds for osteoporosis treatment. 
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3.0  RESULT 
3.1 OSTEOPOROSIS RELATED TARGETS AND DRUGS 
In the current version of OP-KB platform (http://cbligand.org/OP/), we archive 60 
osteoporosis related proteins including 34 validated osteoporosis therapeutic targets with 37 
approved drugs, 33 drugs in clinical trials, 3 discontinued drugs, and 120,371chemicals 
associated with 175,600 records of reported bioactivities from 5,255 corresponding bioassays 
and 1,928 references.  
 
Detailed information of OP-KB is demonstrated in Figure 3. Most of the osteoporosis-
related proteins are enzymes (26/60), including alcohol dehydrogenase 1B, steroid 17-alpha-
hydroxylase/17, 20 lyase, corticosteroid 11-beta-dehydrogenase isozyme 1, insulin-like growth 
factor 1 receptor, mitogen-activated protein kinase 1 and endothelial nitric oxide synthaseand 
cytochrome P450 19A1. There are also 9 membrane proteins, such as the calcitonin receptor, the 
extracellular calcium-sensing receptor, the cannabinoid receptor 1, the cannabinoid receptor 2, 
and the parathyroid hormone-related peptide receptor in addition to 6 proteins belonging to 
transcription factors such as the androgen receptor, the estrogen receptor, the estrogen receptor 
beta, the progesterone receptor and vitamin D3 receptor. (Figure 3A). 
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We next plot anti-OP drugs in different stages of development with projection on their 
therapeutic targets (Figure 3B). As shown, estrogen receptor (ESR1) is considered as the most 
common and successful target for osteoporosis treatment because it has 10 approved drugs, and 2 
drugs entering Phase III clinical trial as well. Farnesyl pyrophosphate synthase (FPPS) and 
androgen receptor (ANDR) seem to be also good targets: both of them have 4 approved drugs. 
However, FPPS has specific bias to bisphosphonates targeting,[68] which may infer that this 
target can’t accomendate other chemotypes easily. Also, we find that 6 cathepsin K (CATK) 
inhibitors are in clinical trials with equal number in phase I, II and III study, indicating cathepsin 
K is a promising drug target for osteoporosis treatment. In addition, vitamin D3 receptor (VDR) 
is also top-ranked with 2 drugs approved and 2 drugs under clinical investigation. But VDR, on 
the other hand, should be paid more careful attention to because it has one discontinued drug, 
Falecalcitriol, that may cause hypercalcemia and bradycardia as adverse effcts.[69] To our 
surprise, cytochrome P450 19A1 (CP19A), a well-known metabolizing enzyme, also functions as 
an anti-OP target for the drug Letrozole, which prevents aromatase from producing estrogens by 
specific binding to the heme of its cytochrome P450 unit.[70] Finally, the OP-related targets-
drugs associations are in connection with involed signaling pathways (Figure 3C). We can see 
that five osteoporosis and bone metabolism related pathways show up in the list (highlighted in 
yellow), including osteoclast differentiation (KEGGID: hsa04380), rheumatoid arthritis 
(hsa05323), estrogen signaling pathway (KEGGID: hsa04915), endocrine and other factor-
regulated calcium reabsorption (KEGGID: hsa04961) and mineral absorption (KEGGID: 
hsa04978). However, some cancer related pathways are also enriched in the list (highlighted in 
green), such as pathways in cancer (hsa05200), proteoglycans in cancer (hsa05205) and prostate 
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cancer (hsa05215). This could imply that osteoporosis shares some common pathways with 
cancer, which means some anti-OP drugs may also act as anti-cancer agents.  
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Figure 3. The overview of OP-KB data. (A) Summary of OP-related proteins. (B) OP drugs in 
different development phases associated with their targets. (C) The associations of OP drugs, 
their corresponding targets, and involved pathways. Only pathways that are assoicated with 
drugs were included and ranked based on the number of invovled targets. In addition, full names 
of pathways were given in the right-upper corner, with those related to opsteoporosis labeled in 
yellow and those related to cancer labeled in green. All abbreviations are listed in Appendix A.  
 
 
 
 
 
 
C 
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3.2 POLYPHARMACOLOGY ANALYSIS OF ANTI-OSTEOPOROSIS DRUGS AND 
THEIR TARGETS 
To explore potential polypharmacological effects for available osteoporosis drugs, we 
utilize the established HTDocking tool to screen all osteoporosis related proteins in our OP-KB 
database.  In this study, we select five representative approved drugs that have different initial 
therapeutic targets. Queried with these five drug structures, a list of potential targets is displayed 
and ranked by docking scores. The five drugs and their top candidate targets (docking score (-
pKd) ≥ 6) are extracted to build an interacting network (Figure 4). Predicted targets are displayed 
as green nodes (known OP targets) and pink nodes (predicted off-targets) with different sizes 
based on the degree of connectivity to drugs. As shown in this figure, all drugs can successfully 
find their known targets in this prediction. For example, Calcitriol is predicted to target VDR, 
and Lasofoxifene is likely to bind with both ESR1 and ESR2. In fact, those predicted targets 
were just primary therapeutic targets for each drug. As such, Calcitriol is a VDR antagonist with 
Ki = 0.1 nM,[71] and Lasofoxifene acts as a dual ESR1 and ESR2 modulator with IC50 equal to 
1.8 nM and 1.3 nM, respectively,[72] which validates the reliability and robustness of our 
database and HTDocking method.  
 
For our group’s research interest on the role of CB2 in osteoporosis therapy, we intend 
to explore if some available drugs also act on CB2 or not. Due to the lack of crystal structure of 
CB2, we take advantage of our built computational 3D CB2 structure model (from Dr. Zhiwei 
Feng, manuscript submitted), predict the potential ligand-binding pocket, and perform molecular 
docking for 5 anti-OP drugs. The method and parameters for pocket prediction and docking are 
the same as HTDocking method. The docking scores are shown in Table 2, in which only 
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Lasofoxifene exhibits high binding potential with CB2 (Docking score = 8.9063). In fact, this 
prediction has been validated by recent studies of Prof. Zhao-Hui Song’s group. They have 
identified Lasofoxifene, together with two other estrogen receptor modulators (Raloxifene and 
Bazedoxifene) as novel CB2 inverse agonists.[73, 74] In order to elucidate the binding mode 
between Lasofoxifene and CB2, we depict the docking result and detailed interaction (Figure 5). 
As shown in Figure 5A, the potential binding pocket of CB2 was mainly formed by helices II, 
III, V, VI, and VII. Lasofoxifene can access this pocket by forming hydrophobic interactions 
(Figure 5B) with nearby residues including Phe94 (not shown), Val105 (now shown), Phe106, 
Ile110, Leu182 (not shown), Trp194, Phe197, Trp258 and Phe281. Among these amino acids, 
Phe87 and Trp258 and can form π-π interactions with two benzene rings in Lasofoxifene, 
respectively. In particular, the N atom in pyrrolidine ring may be protonated to induce 
electrostatic interaction with Asp101 (shown in blue dash), as well as possible π-cation 
interaction with Phe106, both of which help stabilize the binding of Lasofoxifene with CB2. In 
fact, most interacting residues we describe above are supported by published mutational data and 
docking data. Recent docking reports show Phe87, Phe94 and Ile110 may contribute to the 
binding of CB2 ligands, as well as Asp101 which forms hydrogen bonding with CB2 
ligands.[75-77] However, in our case, Asp101 even plays greater roles in forming electrostatic 
interaction. In addition, Leu182 is validated to be unique for CB2 other than CB1 by receptor 
chimera studies.[78] Also, Trp194 is reported to be critical in CB2 binding and corresponding 
adenylyl cyclase activity.[79] Moreover, the replacement of Phe197 with the corresponding Val 
in CB1 causes a 14-fold decrease of Win55212-2 (a CB2 agonist) binding affinity with CB2.[80] 
Lastly, Trp258 is highly conserved for most GPCRs due to its rotameric state involved in GPCR 
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activation.[81] Taken together, almost all residues predicted in the interaction of Lasofoxifene 
with CB2 has been validated to be key residues in the ligand recognition of CB2.  
 
In addition, if we look at this prediction as a whole picture, the targets with relatively 
higher degree of connectivity (the nodes with bigger size) could be more promising in the 
treatment of osteoporosis. The possible explanations are proposed: first, these targets are capable 
of keeping diverse drug molecules staying in their active pockets, which demonstrates the 
druggability of the targets in some degree, and also allows medicinal chemists to design 
structure-diverse chemicals for these targets; second, drugs that act on multiple-ligand binding 
targets are more likely to bind with other targets to achieve polypharmacological effect. In our 
case, the promising osteoporosis therapeutic targets (the degree of connectivity ≥ 3) includes: 
mitochondrial aldehyde dehydrogenase (ALDH2), corticosteroid 11-beta-dehydrogenase 
isozyme 1 (DHI1), sex hormone-binding globulin protein (SHBG), endothelial nitric oxide 
synthase (NOS3) and estrogen receptor (ESR1).  
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Figure 4. Polypharmacology network for OP drugs and predicted OP targets. The large 
circles (blue) represents approved OP drugs (Calcitriol, Letrozole, Estradiol, Lasofoxifene, 
Oxandrolone) that are linked to individual predicted targets. Among them, the green nodes and 
edges denoted known drugs targets and associations, and the pink nodes indicated novel potential 
off-targets connected with drugs by blue dashed edges. The sizes of target nodes varied with the 
degree of connectivity. All abbreviations are listed in Appendix A. 
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Table 2. Docking score of five OP drugs with CB2 receptor 
Drugs Initial Targets 
CB2 Docking 
Score 
Lasofoxifene ESR1, ESR2 8.9063 
Calcitriol VDR 5.6306 
Letrozole CP19A 5.472 
Oxandrolone ANDR 4.9811 
Estradiol ESR1, ESR2 4.3952 
 
      
Figure 5. Interaction mode of CB2with Lasofoxifene via molecular docking. (A) Docking 
result of Lasofoxifene with CB2. Seven trans-membrane domains were indicated in different 
colors; the backbone of Lasofoxifene is shown in purple stick; the predicted binding pocket is 
shown in yellow shape. (B) Detailed interaction of CB2 and Lasofoxifene. The electrostatic 
interaction is indicated by blue dash. (This CB2 model is contributed by Dr. Zhiwei Feng) 
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3.3 POLYPHARMACOLOGY ANALYSIS OF CANNABINOID RECEPTOR 2 
INVERSE AGONISTS 
3.3.1 HTDocking for CB2 inverse agonists 
As stated earlier in section 1.2.2, CB2 inverse agonists have exhibited therapeutic 
potential in the treatment of osteoporosis but with unclear mechanisms of action, especially for 
their anabolic effect of accelerating bone formation. We hypothesize that CB2 inverse agonists 
including our in-house compounds may bind with other OP-related targets for synergic 
regulation of bone metabolism. Hence, we select six CB2 selective inverse agonists (Their 
chemical structures are shown in Figure 6) from literature (AM630,[82] JTE-907,[83] 
Sch.036,[84] and SR144528[85]) or synthesized by ourselves (Xie95-1042[43] and Xie95-
1171[44] are highlighted in blue in Figure 6), and three CB1 selective inverse agonists 
(Rimonabant,[86] CHEMBL425047,[87] and Ibipinabant[88]) as comparison for the 
polypharmacology study. The binding affinities (Ki) and selectivity against CB2/CB1 for these 9 
compounds are shown in Table 3. HTDocking is used to screen out top-ranked OP-related 
proteins as potential targets with the docking score equal to or bigger than 6.0, which has been 
proved to be a reliable threshold value for identifying potential targets in the polypharmacology 
study for marketed OP drugs (Section 3.2). We display the association between the number of 
predicted targets and individual drugs in Figure 7. It is CB2 selective inverse agonists that shows 
more likelihood to act on other OP-related targets other than CB1 inverse agonists. The number 
of predicted off-targets of six CB2 inverse agonists ranges from 6 to 23 with an average number 
of 16.7 per compound.  
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Figure 6. Chemical structures of six representative CB2 inverse agonists. Two in-house 
compounds (Xie95-1042 and Xie95-1171) are highlighted in blue. 
 
Table 3. Binding affinity (Ki) and selectivity for nine CB2/CB1 inverse agonists 
Chemical Names 
Ki (n M) 
Selectivity Reference 
CB2  CB1  
JTE-907 35.9 2370 66 [89] 
AM-630 31.2 5152 165 [89] 
SR144528 0.6 400 667 [89] 
Sch.036 1.3 4387 3375 [90] 
Xie95-1042 64 20000 313 [43] 
Xie95-1171 0.5 1297 2594 [44] 
Rimonabant 1640 11.5 1/143 [89] 
Ibipinabant 7943 7.8 1/1018 [91] 
CHEMBL425047 10000 0.2 1/50000 [87] 
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Figure 7. The number of predicted targets associated with CB2/CB1 inverse agonists. The 
orange color represented the number of targets with docking score ranging between 6 and 7; the 
blue color stood for the number of targets with docking score larger than 7. 
 
We next build the polypharmacology network for these six compounds and their top 
candidate targets (docking score (-pKd) ≥ 6) (Figure 8). In the network, circle nodes indicates 
predicted targets, among which five validated therapeutic targets are labeled in red; rectangle 
nodes stands for compounds. Both of the target nodes and compound nodes are displayed in a 
degree sorted circle layout, respectively. The degree of connectivity is also demonstrated by 
node size and node color. From the network, we find that five known OP targets are identified as 
possible CB2 inverse agonist targets, and four of them had top degree of connectivity (≥ 4) 
except androgen receptor (ANDR). This finding is in agreement with the result of OP drugs-off-
targets network shown in Figure 4, which may suggests that ANDR has a very strict and specific 
ligand structure’s preference. In fact, four available OP drugs targeting ANDR all belongs to the 
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steroids, including Oxandrolone, Methyltestosterone, Testosterone and Testosterone Propionate. 
In addition, we list the docking scores of 6 CB2 inverse agonists with top six predicted targets 
including four potential anti-OP targets (NOS3, DHI1, ALDH2 and TRFL) and two known anti-
OP targets (VDR and ESR1) in Table 4.  
 
Figure 8. Polypharmacology network for CB2 inverse agonists and predicted OP targets. 
The circle nodes indicates predicted targets, among which five known targets were labeled in 
red. The rectangle nodes stood for compounds. Both of the target nodes and compound nodes 
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were displayed in a degree sorted circle layout, respectively. The degree of connectivity was 
demonstrated by node size and node color. The association of the degree of connectivity and 
color is indicated in the right-bottom corner.  
 
Table 4. Docking score of CB2 inverse agonists with anti-OP targets.  
Compound 
Docking score 
NOS3 DHI1 ALDH2 TRFL ESR1 VDR 
Xie95-1042 8.54 8.16 7.78 7.48 8.37 7.88 
Xie95-1171 7.48 7.68 7.97 7.16 7.01 8.87 
AM630 6.22 8.11 7.66 8.16 5.94 6.00 
JTE-907 8.94 7.98 7.00 7.71 7.59 6.93 
Sch.036 6.01 8.20 5.84 5.65 6.01 6.85 
SR144528 7.60 6.36 6.90 6.47 4.67 4.90 
Note: Top two docking scores with four potential anti-OP targets for Xie95-1042, Xie95-1171, 
and AM630 are labeled in red. Docking scores (> 7) with two known anti-OP targets for Xie95-
1042 and Xie95-1171 are labeled in blue. 
 
   In this thesis, we focus on providing an explanation for the fact that our compound 
Xie95-1042 can stimulate osteoblast formation and AM630 can increase the number of 
osteoclasts at high concentration. Meanwhile, we assume that another in-house compound 
Xie95-1171 may also enhance osteoblast formation, which has not been tested yet. To validate 
the predicted targets for these three compounds, we docked each compound to its two most likely 
potential anti-OP targets (top 2 docking scores) (highlighted in red in Table 4), as well as to its 
most likely known anti-OP targets (docking scores >7) (highlighted in blue in Table 4). The 
results and detailed interactions are described in following sections.  
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3.3.2 Potential anti-OP targets for CB2 inverse agonists 
As shown in Figure 8 and Table 4, four OP-related proteins (NOS3, DHI1, ALDH2 and 
TRFL) are highly shared by six CB2 inverse agonists and thereby considered as potential anti-
OP targets. Most of them are the same as those predicted in OP drugs-targets network shown in 
Figure 4. Furthermore, the docking scores for our compounds and AM630 with these four targets 
are all higher than 6. Molecular docking is performed on each compound with its two most likely 
potential targets ((highlighted in red in Table 4) for better identification of reliable ligand-
protein interactions. 
1) Docking result of NOS3 (PDB_ID:1M9K)[92] with Xie95-1042. (Figure 9) 
                
Figure 9. Interaction mode of NOS3 with 7-nitroindazole (A) in co-crystal structure and 
with Xie95-1042 (B) via molecular docking. Hydrogen bonding is indicated by red dash with 
measured distance.  
 
From Figure 9, we can see Xie95-1042 can form hydrogen bonding with Met358 and 
Trp356 of NOS3, which ensembles exactly the hydrogen bonding interactions in the co-crystal 
A B 
Met358 
Trp356 Trp356 
Met358 
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structure of NOS3 and 7-nitroindazole (Hydrogen bonding is indicated by red dash with 
measured distance). Moreover, Xie95-1042 adopts “U-shape” in its binding conformation via 
intramolecular π-π interactions. 
 
2) Docking result of DHI1 (PDB_ID:3D5Q)[93] with Xie95-1042, Xie95-1171, and 
AM630. (Figure 10) 
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Figure 10. Interaction mode of DHI1 with T30 (A) in co-crystal structure and with Xie95-
1042 (B), Xie95-1171 (C), and AM630 (D) via molecular docking. Hydrogen bonding is 
indicated by red dash with measured distance.  
 
From Figure 10, we can see that Xie95-1042, Xie95-1171 and AM630 form two 
hydrogen bonding with Ser170 and Tyr183 of DHI1 (Hydrogen bonding is indicated by red dash 
with measured distance). This observation is in agreement with the DHI1-T30 co-crystal 
structure. In addition, the benzene (at the bottom of molecules) can form π-π interaction with 
Tyr183, as well as hydrophobic interactions with Thr124 and Leu126. Furthermore, all of Xie95-
1042, Xie95-1171 and AM630 adopt U-shape conformation in its binding conformation via 
intramolecular π-π interactions. 
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2) Docking result of ALDH2 (PDB_ID:1NZW)[94] with Xie95-1171. (Figure 11) 
 
 
Figure 11. Interaction mode of ALDH2 with NAPH (A) in co-crystal structure and with 
Xie95-1171 (B) via molecular docking. Hydrogen bonding is indicated by red dash with 
measured distance. Electrostatic interaction is indicated by blue dash.  
 
From Figure 11, we can see that Xie95-1171 can form three hydrogen bonding with 
Lys192, Ile166 and Ser246 of ALDH2 (Hydrogen bonding is indicated by red dash with 
measured distance), which is the same as the hydrogen bonding interactions revealed in ALDH2-
NAPH co-crystal structure. The π-π interaction is also observed between the benzene ring of 
NAPH and Xie95-1171 (at the bottom of molecules) with Phe401. Interestingly, the sulfonyl 
group of Xie95-1171 can chelate with magnesium ion (Mg2+) via π-cation interaction. In fact, the 
similar interaction appears between bi- carbonyl group in NAPH and Mg2+, which may imply the 
specificity of binding between ALDH2 with its ligands.  
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3) Docking result of TRFL (PDB_ID:1CB6)[95] with AM630.  
 
 
Figure 12. Interaction mode of TRFL with AM630. (A) The composition of TRFL and the 
predicted binding pocket at the interface of N lope and C lope (shown in orange shape); (B) 
Detailed interaction of TRFL with AM630. Hydrogen bonding is indicated by red dash with 
measured distance. Halogen bonding is indicated by blue dash with measured distance. 
 
From Figure 12A, we can see that TRFL is composed of two N-terminal domains (N1-
lope and N2-lope) and two C-terminal domains (C1-lope and C2 lope). There is no published co-
crystal structure for TRFL and its bound ligands yet. We use our published method[66] to 
explore the potential binding pocket that is predicted to locate at the interface of N-lope and C-
lope. This prediction is in agreement with the fact that the inter-domain region of TRFL is the 
biggest solvent-accessible surface where the ligands prefer to bind with. Figure 12B depicts the 
detailed binding mode. As shown, hydrogen bonding interactions are observed between AM630 
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and Arg690, Gly406, Arg602, as well as Arg342 (Hydrogen bonding is indicated by red dash 
with measured distance). Moreover, AM630 can form hydrophobic interactions with His246, 
Leu247 and Thr131. Specifically, the iodine atom of AM630 can form halogen bonding with 
Arg342 and Asn330 (Halogen bonding is indicated by blue dash with measured distance).  
3.3.3 CB2 inverse agonists as VDR modulators 
Vitamin D is critically important for bone mineralization via maintaining blood calcium 
level and restore calcium to bone tissue by activating its receptor (VDR).[96] Upon activation, 
VDR forms a heterodimer with the retinoid X receptor and binds to hormone response elements 
on DNA, leading to the expression of certain gene and products that promote calcium absorption 
in the intestine and reabsorption in the kidneys.[96, 97] Moreover, recent studies reveal the direct 
effect of vitamin D on osteoblast proliferation, differentiation and mineralization.[98] Also, the 
transgenic mice overexpressing VDR show increased bone strength.[99] Hence, some vitamin D 
analogues and other VDR agonists can be used as anabolic agents for preventing fractures and 
bone loss in osteoporosis therapy.[100, 101] 
 
Based on our prediction (Figure 8 and Table 4), our in-house CB2 inverse agonists are 
prone to bind with VDR. To validate this and explore the possible mechanism of interactions, we 
dock Xie95-1042 and Xie95-1171 into the VDR protein (PDB_ID: 1DB1).[102] The detailed 
interaction is shown in Figure 13 in comparison with its initial co-crystal structure binding with 
vitamin D.  We can see that Xie95-1042 loses all hydrogen bonding shown in VDR-vitamin D 
co-crystal structure, and Xie95-1171 only keeps two hydrogen bonding with Try143 and Ser278 
of VDR. This may be due to the lack of polar groups in the left benzene ring of these two 
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compounds, which may imply that the binding affinity of VDR and our compounds could be 
enhanced by chemical modification of the left benzene ring. On the other hand, Xie95-1042 and 
Xie95-1171 can form similar hydrophobic interactions with nearby residues including Trp286, 
His305, Arg274, Ser237 and Val234 to those appeared in the co-crystal structure. Among these 
residues, Trp286 can form π-π interaction with Xie95-1042 and Xie95-1171 other than with 
initial ligand vitamin D. This new interaction may compensate the missing hydrogen bonding 
interaction in terms of overall binding affinity. Figure 13D shows the nice alignment of our 
compounds and vitamin D with their binding conformation. We can find that when binding these 
three compounds adopt very close molecular orientation with very similar molecular shape. That 
may explain why these three compounds can fit the same binding pocket of VDR very well.  
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Figure 13. Interaction mode of VDR with vitamin D (A) in co-crystal structure and with 
Xie95-1024 (B), Xie95-1171 (C) via molecular docking. (D) represents the alignment of 
these three compounds by adopting their binding conformations. Hydrogen bonding is 
indicated by red dash with measured distance. 
3.3.4 CB2 inverse agonists as ESR1 modulators 
It is well-known that selective estrogen receptor modulators (SERMs) possess estrogen 
receptor antagonistic or agonistic capability depending on target tissue difference.[103] 
However, in bone tissue, most acted as agonists to exert an estrogen-like effect. For example, 
Raloxifene, the first approved SERM for osteoporosis therapy, can inhibit osteoclasts formation 
and bone resorption while also having a stimulatory effect on osteoblasts to facilitate bone 
formation.[104] On the other hand, ESR1 has been associated strongly with the NOS3 protein 
using a String protein-protein interaction database search (http://string-db.org/). Relevant 
literature identifies that ESR1 agonists can enhance the NOS3 level and the release of nitric 
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oxide (NO), both of which positively contribute for bone formation.[105] Together, ESR1 
agonists can promote bone formation by itself or through the activation of NOS3.  
 
Based on our prediction (Figure 8 and Table 4), CB2 inverse agonists are prone to bind 
with ESR1. There is no direct experimental data to show the binding of CB2 inverse agonists and 
ESR1, but some strongly related research has been published recently. Prof. Zhao-Hui Song has 
identified Raloxifene, a marketed estrogen receptor modulator, as a novel CB2 inverse agonist 
after screening of the 640 FDA-approved drugs.[73] His group confirms two other SERMs 
Bazedoxifene and Lasofoxifene to be CB2 inverse agonists.[74] Hence, it is reasonable for us to 
hypothesize that classical CB2 inverse agonists could also be targeting at ESR1. To validate our 
thought and explore the possible mechanism of interaction, we dock our in-house compounds 
(Xie95-1042 and Xie96-1171) into the ESR1 protein (PDB_ID: 1ERR).[106] The detailed 
interactions are shown in Figure 14 in comparison with its initial co-crystal structure binding 
with Raloxifene.[106] We observe that both Xie95-1042 and Xie95-1171 have hydrophobic 
interactions with Met421, Phe404, His524 and Leu525 of ESR1, and form the edge-to-face π-π 
interaction with Phe404. These observations match quite well this those in Raloxifene-ESR1 co-
crystal structure. Moreover, the tertiary amine in Xie95-1042 and Xie95-1171 may be protonated 
to exert electrostatic interactions with Asp351, which is also in accordance with the observed 
Raloxifene-ESR1 interaction. However, due to the lack of polar groups in the benzene rings for 
our compounds, Xie95-1042 and Xie95-1171 lose hydrogen bonding with nearby residues in 
comparison with co-crystal structure. We assume the missing hydrogen bonding interaction may 
lead to the decreased binding affinity of our compounds with ESR1. We may design new CB2 
inverse agonists with terminal polar benzene rings, which may account for better binding with 
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ESR1. Figure 14D shows the nice alignment of our compounds and Raloxifene with their 
binding conformation. We can find that when binding these three compounds adopt very close 
molecular orientation with very similar molecular shape. That may explain why these three 
compounds can fit the same binding pocket of VDR very well.              
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Figure 14. Interaction mode of ESR1 with Raloxifene (A) in co-crystal structure and with 
Xie95-1042 (B) and Xie95-1171 (C) via molecular docking. Hydrogen bonding is indicated by 
red dash with measured distance. Electrostatic interaction is indicated by blue dash. 
3.3.5 TargetHunter for CB2 inverse agonists off-target prediction 
TargetHunter[67] is a complementary tool for off-target prediction, which exerts 
powerful prediction particularly when protein structures are unrevealed.  Herein, we upload two 
in-house CB2 inverse agonists (Xie95-1042 and Xie95-1171) to our TargetHunter server 
(http://www.cbligand.org/TargetHunter) where a 2D fingerprint similarity search is performed 
between queried compounds and the entire CHEMBL database.[63] The identified similar 
compounds were displayed with the information of their targets, bioactivities and bioassays, and 
ranked according to similarity scores. First of all, we witness that there is no significant 
similarity between our compounds and any compound in the CHEMBL database (all pairwise 
similarity scores ≤ 0.6), suggesting the structural novelty of our compounds. Then we choose the 
most similar compound(s) for Xie95-1042 (CHEMBL1531234 and CHEMBL1416161 with 
equal similarity of 0.55) and also for Xie95-1171: that is CHEMBL1329253 with similarity of 
0.59. These three CHEMBL compounds shares two targets: aldehyde dehydrogenase 1A1 
(ALDH1A1) and glucagon-like peptide 1 receptor (GLP1R), showing biological activity at 10 
μM level (Figure 9). In fact, two classical CB2 inverse agonists, AM-630 and JTE-907, have 
shown inhibition against aldehyde dehydrogenase 1A1 with 5.0 μM and 23.8 μM (PubChem 
assays:1030), respectively. Hence, we propose that our in-house compounds could also bind with 
ALDH1A1. Recent publications report that ALDH1A1 is treated as a useful marker for 
prediction of the clinical outcome of breast cancer subsets[107, 108] and shows a potential role 
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in non-small cell lung carcinogenesis[109] and multiple myeloma.[110] Meanwhile, we know 
that the CB2 inverse agonist has therapeutic potential in cancer treatment.[18, 45, 111, 112] Thus, 
our predicted target ALDH1A1 for in-house CB2 inverse agonists may imply novel mechanism 
for their anti-tumor potency.   
 
Figure 15. TargetHunter used for off-target prediction for in-house CB2 inverse agonists 
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4.0  DISCUSSION 
In summary, our approach provides a paradigm for polypharmacology study on a specific 
disease domain, integrating disease domain knowledgebase construction, structure-based method 
(HTDocking), ligand-based method (TargetHunter) and molecular docking approach (Figure 11). 
 
Figure 16. The paradigm for polypharmacology study on OP specific domain  
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In OP-KB, we compile the data of osteoporosis drugs, targets, related proteins and 
involved pathways, and do further data analysis. We claim that ESR1 is the most successful anti-
OP target because it has the biggest number of marketed drugs (Table 5 in Appendix B). 
Meanwhile, we observe that osteoporosis and cancer share some signaling pathways. Therefore, 
some anti-OP drugs could also function as anti-cancer agents. For example, denosumab, which is 
an antiresorptive agent used for menopausal bone loss, also shows therapeutic potential in 
mammary tumors.[113] Another case is ESR1 modulator such as Lasofoxifene, which has been 
reported to reduce breast cancer risk in postmenopausal osteoporotic women.[114] 
 
In the polypharmacology analysis for five anti-OP drugs, we predict their possible anti-
OP targets. Apart from the good accordance of known targets with predicted targets, other 
potential targets and resulting cross-talk interactions are also observed. For instance, 
Oxandrolone is associated with sex hormone-binding globulin protein (SHBG) as predicted, 
regardless of its established role as an ANDR agonist. Although there is no direct evidence to 
show the binding of Oxandrolone with SHBG, previous study convince that the treatment of 
Oxandrolone can significantly reduce the SHBG level.[115] Again, Letrozole, initially an 
aromatase inhibitor binding with its cytochrome P450 unit, is predicted to target with ESR1. As 
reported in a clinical study, Letrozole can induce the regression of estrogen-dependent tumors 
itself[116] and is commonly used in combination with anti-estrogen drugs for breast cancer 
therapy.[117] Our prediction may allow drug repurposing for Letrozole as an ESR1 antagonist in 
the breast cancer therapy.  
 
 41 
In the polypharmacology analysis for six CB2 inverse agonists, we predict a list of 
potential anti-OP targets for these compounds. Most of the predicted targets are identical to those 
predicted for available anti-OP drugs including the top six candidates (NOS3, DHI1, VDR, 
ALDH2, TRFL, and ESR1). Detailed interactions are proposed via molecular docking between 
these targets and three CB2 inverse agonists (Xie95-1024, Xie95-1171, and AM630), which can 
nicely identify key residues when their binding with initial ligands.  
 
Importantly, the polypharmacology analysis for CB2 inverse agonists also help our 
understanding of their potential role in enhancing the bone formation. In fact, all of six top 
predicted targets are expressed in osteoblast and contributable to osteoblast proliferation. Taking 
NOS3 (the most top possible target) for example, current genetic studies showed some NOS3 
gene polymorphisms like Glu298Asp[118] and variable number tandem repeat (VNTR)[119] 
gene change are implicated in postmenopausal osteoporosis. In coincidence with this, NOS gene-
deficient mice exhibited marked abnormalities in bone volume and formation rate and reduced 
bone mineral density that are mainly due to dysfunctional osteoblasts.[120] Furthermore, DHI1 
has been found to be expressed in osteoblasts and modulated by proinflammatory 
cytokines.[121] It reduces the conversion of cortisone to cortisol that activates glucocorticoid 
receptor (GR). The monomeric GR can suppress proinflammatory cytokines, leading to 
decreased osteoblast differentiation.[122] In terms of ALDH2, a recent publication reports that 
its dominant-negative form, ALDH2*2, can promote osteoporosis due to impaired 
osteoblastogenesis.[123] Another target, TRFL, has shown positive effects on bone turnover by 
decreasing bone resorption and increasing bone formation. This finding is indicated by a change 
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in the levels of distinct bone metabolism markers.[124] As aforementioned, activation of ESR1 
can promote bone formation alone or through the stimulation of NOS3.[104, 105]  
 
On the basis of our prediction, we are more interested in the potential role of some CB2 
inverse agonists as ESR1 modulators inspired by the fact that some ESR1 modulators have been 
validated experimentally as CB2 inverse agonists. On the other hand, ESR1 is currently 
considered as the most successful anti-OP target. We assume that perhaps ESR1 and CB2 share 
some common signaling pathways that are involved in bone cell proliferation and osteoporosis 
development. Therefore, based on the literature reports, we draft the putative downstream 
signaling pathways shared by ESR1 and CB2 (Figure 15). As shown, CB2 and ESR1 are both 
expressed in membrane, which can be activated by the outside signal and accordingly trigger the 
downstream signaling. These two receptors are believed to share four pathways including PI3K-
Akt-anti-apoptosis pathway, PI3K-Akt-NO pathway, PI3K-NF-kB pathway, and Erk1/2-
MAPKAPK2-CREB pathway. Ultimately, all of them exert effects on gene transcription and 
thereby promote cell proliferation. However, we have already known that some compounds such 
as Lasofoxifene and Xie95-1042 can inhibit CB2 while activate ESR1 in bone tissue. People 
may wonder the overall effect of these dual function compounds on bone cell proliferation. We 
consider that the relative binding affinity of compounds with CB2 and ESR1 may count a lot. In 
addition, the expression level of CB2 and ESR1 in different bone cells and the concentration of 
compounds are also contributing factors.  
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Figure 17. Putative signaling pathways shared by ESR1 and CB2 
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5.0  FUTURE SPECULATION 
In this thesis, we use polypharmacology analysis to predict possible targets for CB2 
inverse agonists and some available anti-OP drugs. In the future study, we have some 
considerations as follows: 
 
1) Validation of our off-target prediction by experiments. We proposed some 
potential targets for CB2 inverse agonists in osteoporosis therapy or for drug repurposing 
purpose like NOS3, DHI1, VDR, ALDH2, ESR1, ALDH1A1 and so forth. We are planning to 
find collaborative labs to test the bioactivities/binding affinities of CB2 inverse agonists for those 
proteins. Besides, the follow-up biological functional study by targeting those proteins is also 
necessary to distinguish the inhibition or activation effects. Table 5 provides a recommendation 
target list of five anti-OP drugs and three CB2 inverse agonists for future experimental tests. 
Table 5. Recommendation target list for experimental validation 
Chemicals Primary Targets Shared Predicted Targets 
Lasofoxifene ESR1, ESR2 NOS3, DHI1, ALDH2, MK01, PAI1, LOX12, QPCT, PAI1 
Estradiol ESR1, ESR2 ALDH2, SHBG 
Calcitriol VDR ALDH2,DHI1,SHBG,MK01, TRFL, VTDB 
Letrozole CP19A NOS3, DHI1, ALDH2,ESR1 
Oxandrolone ANDR DHI1, SHBG 
Xie95-1042 CB2 
NOS3, DHI1, VDR, ALDH2, TRFL, ESR1,MK01, ALDH1A1, 
SHBG, QPCT 
Xie95-1171 CB2 
NOS3, DHI1, VDR, ALDH2, TRFL, ESR1,ESR2, PAI1, 
ALDH1A1, LOX12 
AM630 CB2 DHI1, ALDH2, TRFL,ALDH1A1, MK01, QPCT 
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2) Design of multi-target agents for osteoporosis therapy. Our study showed the 
polypharmacological effects of CB2 inverse agonists. Upon experimental validation, we will 
focus on how to transfer polypharmacological concept to practical drug design. Based on our 
published method,[55] we will use fused-pharmacophore modeling approach to design multi-
target agents. The procedure is simply shown in Figure 17. If we tend to design dual-action anti-
osteoporosis agents targeting A and B, we need first build pharmacophore models for both active 
A and B modulators, respectively. Accordingly, we overlap these two models together by 
merging common pharmacophore features. The resulting fused-pharmacophore model will keep 
all distinct pharmacophore features satisfying the dual potency requirements of A and B 
modulators, and thereby can be used in further virtual screening to find new chemotypes with 
expected dual activity for A and B.  
 
Figure 18. Procedure of fused-pharmacophore modeling in the design and discovery of 
dual action agents. 
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APPENDIX A 
ABBREVIATIONS 
ADT3 = ADP/ATP translocase 3 
ALDH1A1 = Aldehyde dehydrogenase 1A1  
ALDH2 = Mitochondrial aldehyde dehydrogenase  
ANDR = Androgen receptor  
ANT3 = Antithrombin-III 
AT2C1 = Calcium-transporting ATPase type 2C member 1 
CALCR = Calcitonin receptor 
CALM = Calmodulin  
CATK = Cathepsin K  
CB1 = Cannabinoid receptor 1  
CB2 = Cannabinoid receptor 2  
COMP = Cartilage oligomeric matrix protein 
CP19A = Cytochrome P450 19A1  
DHB1 = Estradiol 17-beta-dehydrogenase 1 
DHI1 = Corticosteroid 11-beta-dehydrogenase isozyme 1  
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ESR1 = Estrogen receptor 
ESR2 = Estrogen receptor beta  
FA10 = Coagulation factor X 
FAAH = Fatty acid amide hydrolase 
FPPS = Farnesyl pyrophosphate synthase  
GCR = Glucocorticoid receptor 
GLP1R = Glucagon-like peptide 1 receptor  
GSTT1 = Glutathione S-transferase theta-1 
ICAL = Calpastatin 
IGF1R = Insulin-like growth factor 1 receptor 
LOX12 = 12S-type arachidonate 12-lipoxygenase 
LRP6 = Low-density lipoprotein receptor-related protein 6 
MAGL = Monoacylglycerol lipase 
MK01 = Mitogen-activated protein kinase 1 
NOS3 = Endothelial nitric oxide synthase 
PAI1 = Plasminogen activator inhibitor 1 
PK3CA = Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform 
PRGR = Progesterone receptor 
PTH1R = Parathyroid hormone/parathyroid hormone-related peptide receptor 
QPCT = Glutaminyl-peptide cyclotransferase 
SHBG = Sex hormone-binding globulin protein  
ST2A1 = Bile salt sulfotransferase 
ST2B1 = Sulfotransferase family cytosolic 2B member 1 
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TNF11 = Tumor necrosis factor ligand superfamily member 11 
TRFL = Lactotransferrin 
VATA = V-type proton ATPase catalytic subunit A 
VDR = Vitamin D3 receptor  
VKOR1 = Vitamin K epoxide reductase complex subunit 1 
VTDB = Vitamin D-binding protein 
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APPENDIX B 
ANTI-OSTEOPOROSIS DRUGS ON MARTKET OR IN CLINICAL TRIALS 
Table 6. 74 anti-osteoporosis drugs on market or in clinical trials 
No. Status Target DRUG Chemical Structure (SMILES format) 
1 Approved FPPS Alendronic acid NCCCC(O)(P(O)(O)=O)P(O)(O)=O 
2 Phase I TNF11  ALX-0141 Humanized single-domain antibody  
3 Phase II NR1H4 Apomine 
CC(C)OP(=O)(OC(C)C)C(Cc1cc(c(O)c(c1)C(C)(
C)C)C(C)(C)C)P(=O)(OC(C)C)OC(C)C 
4 Phase III ESR1 Arzoxifene 
COc1ccc(cc1)-
c1sc2cc(O)ccc2c1Oc1ccc(OCCN2CCCCC2)cc1 
5 Phase I CASR ATF936 
O=C1N=C(C2=CC=C(C(C)C)C=C2)C3=CC(OC
C#C)=CC=C3N1CC4=CC(OCC)=C(OC)C=C4 
6 Clinical trial Unknown Avicatonin  
CCCC(=O)NC(C)C(=O)NC(CO)C(=O)NC(CC(C
)C)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)NC(C
C)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)N
CC(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)N
C(CO)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O
)O)C(=O)NC(CC(C)C)C(=O)NC(CC1=CN=CN1
)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)N
C(CCC(=O)N)C(=O)NC(C(C)O)C(=O)NC(CC2=
CC=C(C=C2)O)C(=O)N3CCCC3C(=O)NC(CCC
NC(=N)N)C(=O)NC(C(C)O)C(=O)NC(CC(=O)O
)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(C)C(=O)
NCC(=O)NC(C(C)O)C(=O)N4CCCC4C(=O)N 
7 Phase I Unknown AXT914 Unrevealed  
8 Phase III Unknown BA058 human parathyroid hormone-related peptide 
9 Phase II CATK Balicatib 
CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCC
C1)C(=O)NCC#N 
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10 Approved ESR1 Bazedoxifene 
Cc1c(-
c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c
2ccc(O)cc12 
11 Phase II SOST Blosozumab monoclonal antibody IgG4 
12 Phase II SOST BPS-804  human IgG2 monoclonal antibody 
13 Phase II Unknown C3578 Unrevealed  
14 Approved CALCR Calcitonin 
CC(C)CC(NC(=O)C(NC(=O)C1CSSCC(N)C(=O
)NC(CO)C(=O)NC(CC(N)=O)C(=O)NC(CC(C)C
)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)N1)C(C)
C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC(C)
C)C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)N
C(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(Cc1
cnc[nH]1)C(=O)NC(CCCCN)C(=O)NC(CC(C)C
)C(=O)NC(CCC(N)=O)C(=O)NC(C(C)O)C(=O)
NC(Cc1ccc(O)cc1)C(=O)N1CCCC1C(=O)NC(C
CCNC(N)=N)C(=O)NC(C(C)O)C(=O)NC(CC(N
)=O)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CO)C
(=O)NCC(=O)NC(C(C)O)C(=O)N1CCCC1C(N)
=O 
15 Approved VDR Calcitriol 
C[C@H](CCCC(C)(O)C)[C@@]1([H])CC[C@
@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H]
(O)C[C@H](O)C1=C |r| 
16 Phase I ESR2 CHF4227 
COc1ccc(cc1)C1=C(Cc2ccc(OCCN3CCCCC3)cc
2)c2ccc(O)cc2OC1 |c:9| 
17 Approved Unknown Clodronic acid OP(O)(=O)C(Cl)(Cl)P(O)(O)=O 
18 Approved VDR Colecalciferol 
CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]
2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O
)CCC1=C |r| 
19 Approved 
DHB1  
Dehydroepiandrosterone 
[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1(
[H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]
12C |r,t:17| 
ST2A1 
ST2B1 
20 Approved TNF11  Denosumab human IgG2 monoclonal antibody 
21 Approved GCR Dexamethasone 
[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[
C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H]
)CCC2=CC(=O)C=C[C@]12C |r,c:28,t:24| 
22 Clinical trial VDR Doxercalciferol 
CC(C)[C@@](C)([H])\C=C\[C@](C)([H])[C@
@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\
C=C1\C[C@@H](O)C[C@H](O)C1=C |r| 
23 Approved CALCR Elcatonin  
XSNLSTCVLGKLSQQLHKLQTYPRTNTGSG
TX 
24 Phase III VDR Eldecalcitol 
OCCCO[C@@H]1[C@H](O)C\C(=C\C=C2/CC
C[C@]3(C)[C@H](CC[C@@]23[H])[C@H](C)
CCCC(O)(C)C)C(=C)[C@H]1O |r| 
25 Phase II CASR Encaleret 
[H][C@@](O)(CNC(C)(C)Cc1ccc(Cl)c(F)c1)CO
[C@]([H])(C)c1ccccc1-c1ccc(C(O)=O)c(C)c1 |r| 
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26 Approved 
ESR1 
Estradiol 
[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]
1([H])c3ccc(O)cc3CC[C@@]21[H] |r| ESR2 
27 Approved ESR1 Estrone 
[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H
])c3ccc(O)cc3CC[C@@]21[H] |r| 
28 Approved ESR1 Estropipate 
C1CNCCN1.C[C@]12CC[C@H]3[C@@H](CCc
4cc(OS(O)(=O)=O)ccc34)[C@@H]1CCC2=O |r| 
29 Approved PK3CA Etidronic acid CC(O)(P(O)(O)=O)P(O)(O)=O 
30 Discontinued VDR Falecalcitriol 
C=C1\C(=C\C=C2\CCC[C@@]3(C)[C@@]2([H
])CC[C@]3([H])[C@@](C)([H])CCCC(O)(C(F)(
F)F)C(F)(F)F)C[C@@]([H])(O)C[C@]1([H])O 
|r| 
31 Approved ESR1 Fosfestrol 
CC\C(=C(\CC)c1ccc(OP(O)(O)=O)cc1)c1ccc(OP
(O)(O)=O)cc1 
32 Approved ANT3 Heparin 
CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2
C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC
4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(
=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O 
33 Approved FPPS Ibandronic acid CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O 
34 Approved Unknown Ipriflavone CC(C)Oc1ccc2c(c1)occ(-c1ccccc1)c2=O 
35 Approved ESR1 Lasofoxifene 
Oc1ccc2[C@H]([C@H](CCc2c1)c1ccccc1)c1ccc
(OCCN2CCCC2)cc1 |r| 
36 Approved CP19A Letrozole 
C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)
N3C=NC=N3 
37 Phase III ESR1 Levormeloxifene 
COc1ccc2[C@H]([C@H](c3ccccc3)C(C)(C)Oc2
c1)c1ccc(OCCN2CCCC2)cc1 |r| 
38 Clinical trial ANDR LGD2941 
FC(F)(F)CN(CC(F)(F)F)c1ccc2[nH]c(=O)cc(c2c
1)C(F)(F)F 
39 Approved 
ESR1 
Medroxyprogesterone 
[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)
CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=
CC(=O)CC[C@]12C |r,t:22| 
PRGR 
40 Approved 
ESR1 
Medroxyprogesterone 
acetate 
[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@
@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](
C)C2=CC(=O)CC[C@]12C |r,t:25| 
PRGR 
41 Approved ANDR Methyltestosterone 
[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@
@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]1
2C |r,t:19| 
42  Phase III FPPS Minodronic acid OC(Cc1cnc2ccccn12)(P(O)(O)=O)P(O)(O)=O 
43 Phase II 
Integrin 
αVβ3 
MK0429 
COC1=NC=C(C=C1)[C@H](CC(O)=O)N1CCN(
CCCC2=NC3=C(CCCN3)C=C2)C1=O 
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44 Phase II Unknown MK5442 
CC1=C(C=CC(=C1)C2=CC=CC=C2C(C)OCC(C
NC(C)(C)CC3=CC(=C(C=C3)Cl)F)O)C(=O)O 
45 Clinical trial FPPS Neridronic acid NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O 
46 Phase II PGH2 Nitroflurbiprofen 
CC(C(=O)OCCCCO[N+]([O-
])=O)c1ccc(c(F)c1)-c1ccccc1 
47 Preclinical CASR  NPS2143 
CC(C)(Cc1ccc2ccccc2c1)NC[C@H](O)COc1ccc
c(Cl)c1C#N |r| 
48 Phase III CATK Odanacatib 
CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-
c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC
1)C#N |r| 
49 Clinical trial FPPS Olpadronic Acid CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O 
50 Phase II CATK ONO-5334 Unrevealed  
51 Approved ESR1 Ospemifene 
OCCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc
1 
52 Discontinued TNF11  Osteoprotegerin  Protein 
53 Approved ANDR Oxandrolone 
CC12CCC3C(C1CCC2(C)O)CCC4C3(COC(=O)
C4)C 
54 Approved GCR Prednisolone 
[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C
)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=
CC(=O)C=C[C@]12C |r,c:27,t:23| 
55 Approved PTH1R Preotact Parathyroid hormone human 
56 Phase I Unknown PTH134 
SVSEIQLMHNLGKHLNSMERVEWLRKKLQ
DVHNF 
57 Clinical trial Unknown PTHY 
SVSEIQLMHNLGKHLNSMERVEWLRKKLQ
DVHNFVALGAPLAPRDAGSQRPRKKEDNV
LVESHKSGEADKADVNVLTKAKSQ 
58 Approved 
ESR1 
Raloxifene 
Oc1ccc(cc1)-
c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)
cc1 
ESR2 
59 Phase I CATK Relacatib 
CC(C)C[C@H](NC(=O)c1cc2ccccc2o1)C(=O)N[
C@H]1CC[C@@H](C)N(CC1=O)S(=O)(=O)c1c
cccn1 |r| 
60 Approved FPPS Risedronic acid OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O 
61 Phase III SOST Romosozumab  
humanized monoclonal antibody of 
Immunoglobulin G2 
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62 Phase II CASR Ronacaleret 
CC(C)(CC1Cc2ccccc2C1)NC[C@@H](O)COc1c
c(CCC(O)=O)cc(F)c1F |r| 
63 Discontinued 
Integrin 
αVβ3 
SB273005 
CNc1cccc(CCOc2ccc3C[C@@H](CC(O)=O)C(=
O)N(CC(F)(F)F)Cc3c2)n1 |r| 
64 Phase I Unknown Sotatercept  
Homo sapiens ACVR2A, 21-135 precursor 
fragment (1-115) -threonyl-triglycyl linker (116-
119) -gamma1 chain H-CH2-CH3 fragment (120-
344) 
65 Approved Unknown Strontium ranelate 
[Sr++].[Sr++].[O-]C(=O)CN(CC([O-
])=O)c1sc(C([O-])=O)c(CC([O-])=O)c1C#N 
66 Approved PTH1R Teriparatide 
SVSEIELMHDLKHLDSMERVEWLRKKLEDV
HDF 
67 Approved ANDR Testosterone 
[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@
@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]1
2C |r,t:18| 
68 Approved ANDR Testosterone Propionate 
[H][C@@]12CC[C@H](OC(=O)CC)[C@@]1(C
)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C
C[C@]12C |r,t:22| 
69 Approved VATA Tiludronic acid OP(O)(=O)C(Sc1ccc(Cl)cc1)P(O)(O)=O 
70 Approved 
ANT3 
Tinzaparin Unrevealed  
AT2C1 
CALM 
COMP 
FA10 
ICAL 
71 Phase I CATK VEL0230 
CC(C)COC[C@H](CC(C)C)NC(=O)[C@H]1O[
C@@H]1C(O)=O |r| 
72 Phase III 
BGLAP 
Vitamin K1 
CC(C)CCCC(C)CCCC(C)CCC\C(C)=C\CC1=C(
C)C(=O)c2ccccc2C1=O |c:20| 
OSTC 
VKGC 
73 Approved VKOR1 Warfarin CC(=O)CC(c1ccccc1)c1c(O)oc2ccccc2c1=O 
74 Approved FPPS Zoledronic acid OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O 
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